Awardee OrganizationWITS HEALTH CONSORTIUM (PTY), LTD
Description
Abstract Text
Project Summary:
Tuberculosis (TB) is the leading cause of infectious disease deaths globally. With TB incidence
currently decreasing by 2% annually, achieving the World Health Organization’s ENDTB goal
of TB elimination by 2050 will require a substantial reworking of our TB control approach.
Previous elimination strategies for other diseases have only been successful once spatial
variation in disease incidence was identified and then locally relevant interventions
implemented. TB elimination strategies require longitudinal TB cohorts that incorporate
detailed spatial information. South Africa is an ideal setting for our work with both the second
highest TB incidence globally and a central National Health Laboratory Service (NHLS)
database of routinely-collected laboratory results. We propose to develop a ten-year national
TB cohort with the ability to track patients for up to ten years, including spatial location data
and HIV status, using national NHLS data. We hypothesize that NHLS data can be used to
identify key metrics in the TB care cascade, at the facility level, and evaluate the impact of HIV
treatment scale-up and the roll-out of new diagnostics on the TB epidemic in South Africa. In
aim 1a we will use probabilistic record linkage to create unique patient identifiers in the NHLS
data for all TB patients, allowing us to link an individual’s test results and track those confirmed
cases spatially and temporally, and incorporating HIV test results. In aim 1b, we will identify
key steps in the TB care cascade and augment our ten-year cohort with data from clinic chart
reviews. In aim 1c, we will identify locations with gaps in specific care cascade steps, common
patient movement patterns during TB treatment and identify locations with potential higher
burden of disease based on molecular test variables. In aim 2 we will quantify the relationship
between HIV treatment levels and TB incidence, at the facility level. In aim 3 we will evaluate
the association between GeneXpert Ultra “trace” results and repeat TB episodes to enhance
the interpretation of these new diagnostic results. This contribution is significant because it will
develop a national ten-year cohort of TB patients tracking them longitudinally and spatially
during treatment, enabling local public health professionals to develop locally appropriate
interventions to close gaps in the TB care cascade and understand the impact of interventions
and new TB diagnostics. The proposed work is innovative because it will provide the first
cohort of this kind in a high burden setting, with the longitudinal and spatial nature of these
data allowing for unprecedented capture of TB care and the impact of interventions. This will
allow policy makers to design locally-relevant interventions targeting specific gaps in TB care
and highly mobile populations, preventing further spread and ultimately reducing disease and
mortality due to TB. By using routinely collected laboratory data, our model adds minimal
financial costs and can be adapted for similar TB high-burden, middle-income settings with
large laboratory datasets.
Public Health Relevance Statement
PROJECT NARRATIVE
The proposed research is relevant to public health because it will provide a framework to use routinely
collected South African laboratory data to track tuberculosis (TB) patients through time and space,
incorporating HIV data. This will allow us to define the TB care cascade nationally and by facility
(clinic/hospital), incorporating patients’ movements, thus enabling the targeting of these locations with locally
appropriate interventions. We will also be able to evaluate the impact of HIV treatment scale-up and
introduction of new TB diagnostics on TB morbidity and mortality – directly relevant to the NIH’s mission of
reducing morbidity and mortality due to tuberculosis.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AccountingAddressAftercareAlgorithmsAreaBenchmarkingCaringCategoriesCessation of lifeClinicClinics and HospitalsCommunicable DiseasesCountryDNADataData SetData SourcesDatabasesDiagnosisDiagnosticDiseaseDisease ProgressionDrug resistance in tuberculosisEpidemicEvaluationFinancial costGoalsHIVHIV diagnosisHIV/TBHealthHealth ProfessionalHuman immunodeficiency virus testIncidenceIncomeIndividualInfectionInfrastructureInterventionKnowledgeLaboratoriesLinkLocationLongitudinal cohortMapsMethodsMissionModelingMoldovaMolecularMonitorMorbidity - disease rateMovementMycobacterium tuberculosisNatural HistoryNatureOutcomePatientsPatternPersonsPoliciesPolicy MakerPoliomyelitisPopulationPrevalenceProvincePublic HealthRecordsRelapseReportingResearchRisk FactorsServicesSmallpoxSouth AfricaSouth AfricanTemperatureTest ResultTestingTimeTuberculosisUnited States National Institutes of HealthVariantViralWorkWorld Health Organizationburden of illnesscohortdesigndiagnostic algorithmdisorder riskglobal healthimprovedinfection rateinnovationlongitudinal caremeltingmigrationmortalitynovelnovel diagnosticsnovel therapeuticspreventprogramsscale upsurveillance datatesting servicestransmission processtreatment durationtuberculosis diagnosticstuberculosis treatment
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
639391218
UEI
KNNNGEN9MQB8
Project Start Date
13-April-2020
Project End Date
31-March-2026
Budget Start Date
01-April-2024
Budget End Date
31-March-2026
Project Funding Information for 2024
Total Funding
$313,617
Direct Costs
$302,413
Indirect Costs
$11,204
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$313,617
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI152126-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI152126-05
Patents
No Patents information available for 5R01AI152126-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI152126-05
Clinical Studies
No Clinical Studies information available for 5R01AI152126-05
News and More
Related News Releases
No news release information available for 5R01AI152126-05
History
No Historical information available for 5R01AI152126-05
Similar Projects
No Similar Projects information available for 5R01AI152126-05